Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Relish the World: Notable Caf\u00e9s You Really want to Attempt - 2Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
- 3Vinicultural Investigation: A Survey of \Enjoying Fine Vintages\ Wine sampling
- 4The Tradition of Stone: A Gander at Notable Structures Through the Ages
- 5James Webb Space Telescope watches 'Jekyll and Hyde' galaxy shapeshift into a cosmic monster
- They died 'doing what they loved': The stories of workers in their 80s who died on the job
- The face is familiar, the name might not be. The king of "Hey, it's that guy!' roles is ready to show you his next act.
- Roche breast cancer pill cuts risk of disease recurrence by 30% in trial
- Going on a bad date is a drag. Worse? Ending up as a cautionary tale on TikTok.
- The Drone Video of the Year is stunning – you've not seen Namibia like this
- Overlooked infertility care should be part of national health services, says WHO
- Journey Lines for Each Explorer: Track down Your Ideal Journey
- \Step by step instructions to Pick the Best Material Organization for Your Home\
- RFK Jr. succeeds in changing hepatitis B recommendation | The Excerpt
